• Je něco špatně v tomto záznamu ?

Elipse, the first procedureless gastric balloon for weight loss: a prospective, observational, open-label, multicenter study

E. Machytka, S. Gaur, R. Chuttani, M. Bojkova, T. Kupka, M. Buzga, A. Giannakou, K. Ioannis, E. Mathus-Vliegen, S. Levy, I. Raftopoulos,

. 2017 ; 49 (2) : 154-160. [pub] 20161212

Jazyk angličtina Země Německo

Typ dokumentu klinické zkoušky, časopisecké články, multicentrická studie, pozorovací studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc18034037

Background and study aims Conventional gastric balloons for weight loss require endoscopy for placement and removal. The Elipse device is swallowed, resides in the stomach for 4 months, and is then expelled. The objectives of this study were to assess the safety of Elipse and to measure its effects on weight loss, metabolic parameters, and quality of life. Methods Each participant swallowed one Elipse device, which was filled with 550 mL of filling fluid through a thin delivery catheter that was then removed. Weight was measured every 2 weeks, and metabolic parameters and quality of life were assessed at baseline and at trial exit. Results 34 patients, with a mean body mass index of 34.8 kg/m2, were enrolled. All 34 patients successfully swallowed the Elipse device. All adverse events were either self-limiting or resolved with medication. All balloons were safely excreted. At 4 months, the mean percent total body weight loss was 10 %. Mean waist circumference was reduced by 8.4 cm. Improvements were also seen in hemoglobin A1c, triglycerides, low density lipoprotein, and blood pressure. At trial exit, quality of life measures had improved across all domains. Conclusion These results demonstrate clinically significant weight loss with the Elipse, the first procedureless gastric balloon. The weight loss was similar to that seen in previous studies of endoscopically placed balloons. In addition, Elipse therapy led to improvements in waist circumference, several metabolic parameters, and overall quality of life.ClinicalTrials.gov identifier: NCT 02802007.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18034037
003      
CZ-PrNML
005      
20181026102735.0
007      
ta
008      
181008s2017 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1055/s-0042-119296 $2 doi
035    __
$a (PubMed)27951610
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Machytka, Evzen $u Internal Clinic, Department of Gastroenterology, University Hospital Ostrava, Ostrava, Czech Republic.
245    10
$a Elipse, the first procedureless gastric balloon for weight loss: a prospective, observational, open-label, multicenter study / $c E. Machytka, S. Gaur, R. Chuttani, M. Bojkova, T. Kupka, M. Buzga, A. Giannakou, K. Ioannis, E. Mathus-Vliegen, S. Levy, I. Raftopoulos,
520    9_
$a Background and study aims Conventional gastric balloons for weight loss require endoscopy for placement and removal. The Elipse device is swallowed, resides in the stomach for 4 months, and is then expelled. The objectives of this study were to assess the safety of Elipse and to measure its effects on weight loss, metabolic parameters, and quality of life. Methods Each participant swallowed one Elipse device, which was filled with 550 mL of filling fluid through a thin delivery catheter that was then removed. Weight was measured every 2 weeks, and metabolic parameters and quality of life were assessed at baseline and at trial exit. Results 34 patients, with a mean body mass index of 34.8 kg/m2, were enrolled. All 34 patients successfully swallowed the Elipse device. All adverse events were either self-limiting or resolved with medication. All balloons were safely excreted. At 4 months, the mean percent total body weight loss was 10 %. Mean waist circumference was reduced by 8.4 cm. Improvements were also seen in hemoglobin A1c, triglycerides, low density lipoprotein, and blood pressure. At trial exit, quality of life measures had improved across all domains. Conclusion These results demonstrate clinically significant weight loss with the Elipse, the first procedureless gastric balloon. The weight loss was similar to that seen in previous studies of endoscopically placed balloons. In addition, Elipse therapy led to improvements in waist circumference, several metabolic parameters, and overall quality of life.ClinicalTrials.gov identifier: NCT 02802007.
650    _2
$a dospělí $7 D000328
650    _2
$a index tělesné hmotnosti $7 D015992
650    _2
$a dilatace $x škodlivé účinky $x přístrojové vybavení $x metody $7 D004106
650    _2
$a design vybavení $7 D004867
650    _2
$a ženské pohlaví $7 D005260
650    12
$a žaludeční balónek $7 D015905
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a obezita $x diagnóza $x patofyziologie $x psychologie $x terapie $7 D009765
650    12
$a kvalita života $7 D011788
650    _2
$a výsledek terapie $7 D016896
650    12
$a hmotnostní úbytek $7 D015431
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a pozorovací studie $7 D064888
700    1_
$a Gaur, Shantanu $u Allurion Technologies, Wellesley, Massachusetts, USA.
700    1_
$a Chuttani, Ram $u Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
700    1_
$a Bojkova, Martina $u Internal Clinic, Department of Gastroenterology, University Hospital Ostrava, Ostrava, Czech Republic.
700    1_
$a Kupka, Tomas $u Internal Clinic, Department of Gastroenterology, University Hospital Ostrava, Ostrava, Czech Republic.
700    1_
$a Buzga, Marek $u Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
700    1_
$a Giannakou, Andreas $u Department of Surgery, Iatriko Medical Center, Palaio Faliro, Greece.
700    1_
$a Ioannis, Kandiliotis $u Department of Radiology, Iatriko Medical Center, Palaio Faliro, Greece.
700    1_
$a Mathus-Vliegen, Elisabeth $u Department of Gastroenterology and Hepatology, Academic Medical Centre, University of Amsterdam, Amsterdam, Netherlands.
700    1_
$a Levy, Samuel $u Allurion Technologies, Wellesley, Massachusetts, USA.
700    1_
$a Raftopoulos, Ioannis $u Department of Surgery, Iatriko Medical Center, Palaio Faliro, Greece. Comprehensive Weight Loss Institute, Holyoke Medical Center, Holyoke, MA, USA.
773    0_
$w MED00009605 $t Endoscopy $x 1438-8812 $g Roč. 49, č. 2 (2017), s. 154-160
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27951610 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20181008 $b ABA008
991    __
$a 20181026103246 $b ABA008
999    __
$a ok $b bmc $g 1340407 $s 1031031
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 49 $c 2 $d 154-160 $e 20161212 $i 1438-8812 $m Endoscopy $n Endoscopy $x MED00009605
LZP    __
$a Pubmed-20181008

Najít záznam

Citační ukazatele

Možnosti archivace